Diabetes Drugs Market Status 2018-2022
The global diabetes market has been growing steadily in recent years, with the global diabetes drug market reaching USD 83 billion in 2018 and is expected to exceed USD 124 billion by 2022.

Global Diabetes Market Size and Growth 2015-2022
The U.S. dominates the global diabetes drug market due to the large number of people suffering from diabetes. According to the World Health Organization, 9.6% of the total U.S. population was suffering from diabetes in 2016. In addition to this, increasing number of obesity, changing lifestyle, and increasing healthcare expenditure are contributing to the growth of the U.S. diabetes medication market. Elevated cholesterol levels and smoking increase the likelihood of developing diabetes. According to the CDC (2014), 73.5 million adults in the U.S. have been diagnosed with high cholesterol levels. In addition, increasing awareness about different monitoring procedures, increased awareness, and development of advanced technologies are also contributing to the growth of the diabetes medications market.
Europe is the second largest market for diabetes medications, followed by Asia Pacific. The large smoking population, availability of research funding, and government support for research and development will drive the diabetes drugs market in Europe.
Asia Pacific is the fastest growing region in the diabetes drugs market, attributed to the large patient population, continuous economic development, and increasing demand for better treatments.
On the other hand, the Middle East and Africa has the least share in the global diabetes drugs market due to the economic downturn, especially in Africa. The Middle East holds a major share of the diabetes drugs market in the Middle East and Africa due to a well-developed healthcare sector and huge healthcare expenditure.
Looking for chemical products? Let suppliers reach out to you!
2026-07-03
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
China State Drug Administration officially approved Semaglutide for type 2 diabetes
-
Diabetes Drugs Market Competitive Landscape
-
NHU and Sinopec Advance Liquid Methionine Project
-
West Asia’s Conflict Is Testing the Hidden Fragility of Pharma Trade
-
China’s Approval of Pfizer’s GLP-1 Drug Signals a Sharper Obesity Race
-
South Africa Wants Lenacapavir at Home, Not Just Imported
-
Affordable GLP-1s Could Rewrite the Global Obesity Market
-
A Cold-Chain Crackdown in Delhi Sends a Much Bigger Message
-
Torrent Pharma Targets First Wave Semaglutide Launch Revenue Up 11 Percent as Patent Ends
-
Hengrui Strikes $500 Million Global Drug Deal with GSK Potential Payouts Up to $12 Billion
Recommend Reading
-
Parliamentary Panel Urges Expanded Price Controls as Dozens of Cancer Drugs Remain Unregulated
-
₹27,548 Crore Pharma Giant Cipla Enters Weight Management Battle as Obesity Demand Surges
-
Glenmark Recalls Over 110000 Bottles of BP and COPD Drugs in US Due to Safety Concerns
-
60 Percent Workforce Held by Top 10 Firms! China’s TCM Industry Faces Fierce Reshuffle as Private Leaders Expand Fast
-
Novo Nordisk Reports Theft of Six Drug Batches in India Authorities Warn of Severe Patient Safety Risks
-
Coking Coal Market Prices Rise in July
-
PPG and Asian Paints Extend 30-Year Strategic Partnership, Deepening Market Presence in India
-
DKSH Upgrades its Malaysia Innovation Center to Strengthen Technical Service Capabilities for the Southeast Asian Market
-
Axplora Expands Indian Market: €6.5 Million to Expand API Manufacturing in Vizag
-
Ample Supply, Acrylonitrile Prices Fluctuate Downward